Categories: December 09

Quant Snapshot: Aastra Technologies (TSX:AAH)

Underlying data:

1. Price to sales: 0.49

As of Q1, 2009 Aastra had 13.43 million shares outstanding. The price
as of April 22, 2009 was $30.65 This gave The Company a market
capitalization of $411.62 million.  In the trailing four quarters sales
totaled $832.06 million.

2. Cash to market cap:6.85%

As of Q4, 2008 reported cash and short term investments was $57.86 million. Market cap as of April 6, 2009 was $411 million.

3. Debt to market cap:8.66%

The Company reported  long term debt  of $35.54 million as of Q1, 2009.

4. Three year growth rate: 19.36%

Sales for fiscal 2005 were $500.76 million. Sales grew to $832 million in fiscal 2008.

5. Enterprise value to sales: 52%

The Company’s Enterprise Value as of Q1 2009 was $433.32 million
using the formula (market cap + long term debt – cash and short term
investments). Sales for the trailing 4Q’s were $832.06 million

SuperUser

Recent Posts

Perimeter Medical Imaging wins price target raise from this analyst

In an April 8 note, Paradigm Capital analyst Scott McAuley maintained his “Speculative Buy” rating on Perimeter Medical Imaging AI… [Read More]

52 minutes ago

The analyst still loves Kits Eyecare

Beacon Securities analyst Doug Cooper said preliminary first-quarter results from Kits Eyecare (Kits Eyecare Stock Quote, Chart, News, Analysts, Financials… [Read More]

1 hour ago

Blackline Safety shareholders should take the deal, this analyst says

Ventum Capital Markets analyst Amr Ezzat moved Blackline Safety (Blackline Safety Stock Quote, Chart, News, Analysts, Financials TSX:BLN) to “Tender”… [Read More]

15 hours ago

Is The FUTR Corporation still a buy?

Research Capital analyst Greg McLeish maintained his “Speculative Buy” rating and $3.00 target on The FUTR Corporation (The FUTR Corporation… [Read More]

20 hours ago

This investor likes Vanguard FTSE right now

In an appearance on BNN Bloomberg Market Call on April 2, RN Croft Financial Group portfolio manager Richard Orrell highlighted… [Read More]

1 day ago

This new development makes WELL Health worth more, analyst says

In an April 8 note, Stifel analyst Justin Keywood maintained his “Buy” rating and C$8.00 target on WELL Health Technologies… [Read More]

1 day ago